Article
VitrenASE: Immusol starts trial for potential PVR drug
San Diego-Immusol has begun a phase II clinical trial for its VitrenASE, a potential treatment for proliferative vitreoretinopathy (PVR) that could reduce the incidence of repeat retinal detachment after surgical repair.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Videos
Aerie Pharmaceuticals CEO discusses what's new in the pipeline
ImprimisRx offers a look at three new products in the pipeline
Visus CEO updates on lead product candidate, 2021 pipeline
(AAO) Genentech provides update on presentations, product portfolio
What keeps you up at night in ophthalmology: Part II
Glaucoma 360: Drug delivery contact lens technology
Glaucoma 360: Pharmaceuticals in the glaucoma industry
Related Content
